- Home
- STLA vs IQV Comparison
STLA vs IQV Comparison
Compare STLA & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STLA | IQV |
|---|---|---|
| Founded | 2021 | 1982 |
| Country | Netherlands | United States |
| Employees | 248243 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7B | 36.4B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | STLA | IQV |
|---|---|---|
| Price | $11.06 | $241.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $11.99 | ★ $236.93 |
| AVG Volume (30 Days) | ★ 9.1M | 1.2M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.30 |
| Revenue | ★ $171,605,402,237.00 | $15,904,000,000.00 |
| Revenue This Year | $0.20 | $6.15 |
| Revenue Next Year | $5.45 | $5.39 |
| P/E Ratio | ★ N/A | $32.12 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $8.39 | $134.65 |
| 52 Week High | $14.28 | $234.95 |
Technical Indicators
Market Signals| Indicator | STLA | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 72.16 |
| Support Level | $10.88 | $221.78 |
| Resistance Level | $11.47 | $228.28 |
| Average True Range (ATR) | 0.17 | 4.32 |
| MACD | -0.07 | 1.15 |
| Stochastic Oscillator | 16.52 | 96.06 |
Price Performance
Historical ComparisonAbout STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.